(Q24248702)

1

0 references

A Solari

2

0 references

R D'Amico

3

0 references

P Branãs

4

0 references

C Hyde

5

0 references

G Giuliani

Cochrane Database of Systematic Reviews

6

0 references

publication date

22 April 2003

0 references

published in

0 references

cites work

Amantadine treatment of fatigue associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

Amantadine, fatigue, and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

The measurement of fatigue: A new instrument

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

A method for assessing the quality of a randomized control trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Amantadine therapy for fatigue in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Amantadine influences cognitive processing in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Effectiveness of amantadine in reducing relapses in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021

Treatments for fatigue in multiple sclerosis: a rapid and systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002818

7 January 2021